Preclinical ASO Portfolio

About Isarna Therapeutics

Isarna Therapeutics is a private, clinical-stage biotech leveraging deep expertise in antisense oligonucleotide design to target TGF-β, a key mediator of fibrosis and disease progression. The company has built a portfolio targeting specific TGF-β isoforms, with its lead program in Phase 2a for retinal diseases and preclinical assets for NASH and cancer. Backed by a syndicate of German venture capital and public investors, Isarna aims to pioneer a new class of therapeutics in a complex but high-potential biological pathway.

About Isarna Therapeutics

Isarna Therapeutics is a private, clinical-stage biotech leveraging deep expertise in antisense oligonucleotide design to target TGF-β, a key mediator of fibrosis and disease progression. The company has built a portfolio targeting specific TGF-β isoforms, with its lead program in Phase 2a for retinal diseases and preclinical assets for NASH and cancer. Backed by a syndicate of German venture capital and public investors, Isarna aims to pioneer a new class of therapeutics in a complex but high-potential biological pathway.

Therapeutic Areas